Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00424788 | A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) | EARLY_PHASE1 | COMPLETED | 12 | — | — | Jan 1, 2007 | Oct 1, 2007 | Sep 4, 2009 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| Plasma exchange | PROCEDURE | - |
| natalizumab treatment | DRUG | - |
Inclusion Criteria: * considered by the Investigator to be free of signs and symptoms suggestive of any serious opportunistic infection * willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including interferon beta and glatiramer acetate) for th...